These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1295 related articles for article (PubMed ID: 28499366)
1. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion. Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366 [TBL] [Abstract][Full Text] [Related]
2. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Blanchard Z; Paul BT; Craft B; ElShamy WM Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261 [TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India. ; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553 [TBL] [Abstract][Full Text] [Related]
4. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291 [TBL] [Abstract][Full Text] [Related]
5. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602 [TBL] [Abstract][Full Text] [Related]
6. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt. Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605 [TBL] [Abstract][Full Text] [Related]
7. The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. Ryan D; Paul BT; Koziol J; ElShamy WM Breast Cancer Res; 2019 Apr; 21(1):53. PubMed ID: 31014367 [TBL] [Abstract][Full Text] [Related]
8. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India. Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142 [TBL] [Abstract][Full Text] [Related]
10. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study. Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182 [TBL] [Abstract][Full Text] [Related]
12. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study. Podo F; Santoro F; Di Leo G; Manoukian S; de Giacomi C; Corcione S; Cortesi L; Carbonaro LA; Trimboli RM; Cilotti A; Preda L; Bonanni B; Pensabene M; Martincich L; Savarese A; Contegiacomo A; Sardanelli F Clin Cancer Res; 2016 Feb; 22(4):895-904. PubMed ID: 26503945 [TBL] [Abstract][Full Text] [Related]
13. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages? Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691 [TBL] [Abstract][Full Text] [Related]
14. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India. Chandra D; Suresh P; Sinha R; Azam S; Batra U; Talwar V; Kumar K; Mehta A Asian Pac J Cancer Prev; 2016; 17(6):2995-9. PubMed ID: 27356724 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India. Nabi MG; Ahangar A; Wahid MA; Kuchay S Niger J Clin Pract; 2015; 18(3):381-6. PubMed ID: 25772923 [TBL] [Abstract][Full Text] [Related]
16. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197 [TBL] [Abstract][Full Text] [Related]
17. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer]. Ma JG; Wang NJ; Yu WJ Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778 [TBL] [Abstract][Full Text] [Related]
18. Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience. Der EM; Gyasi RK; Tettey Y; Edusei L; Bayor MT; Jiagge E; Gyakobo M; Merajver SD; Newman LA Breast J; 2015; 21(6):627-33. PubMed ID: 26547900 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases. Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. Boukerroucha M; Josse C; ElGuendi S; Boujemla B; Frères P; Marée R; Wenric S; Segers K; Collignon J; Jerusalem G; Bours V BMC Cancer; 2015 Oct; 15():755. PubMed ID: 26490435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]